

## **New data on MIV-818 will be presented at EASL's International Liver Congress™ 2017**

**Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR)** today informs that preclinical data on MIV-818 will be presented by Medivir at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April. The poster presentation, abstract SAT-123, is entitled “Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers” and will include data on the anticancer activity and pharmacokinetic profile of MIV-818.

Details of all presentations for The International Liver Congress™ 2017 are available at the website: <http://www.easl.eu/>.

### **For further information, please contact:**

Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211  
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

### **About Medivir**

Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.